Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu

Pfizer and Arvinas have landed on a buyer for newly approved breast cancer med Veppanu, selling off an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and hundreds of mill The deal includes up to $320 million in future milestone payments plus tiered royalties on Veppanu sales, which will be split evenly between Arvinas and Pfizer. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources…

Source: FiercePharma